Human papillomavirus is responsible for common condyloma acuminata and a number of premalignant and malignant anogenital lesions. The immunocompromised population is at particular risk because of a higher incidence of malignant transformation. Lesions in this population may prove refractory to standard treatment. This is part II of a two-part review that will discuss the treatment of condyloma acuminata and vaginal, vulvar, penile, and anal intraepithelial neoplasias. This article will provide an updated review of available treatments, with a focus on recent advances and the challenges faced in successfully treating human papillomavirus lesions in the immunocompromised host.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jaad.2010.12.049 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!